Enhanced Targeted Therapy for Autoimmune Diseases using Liposomal Delivery

A novel approach to treating autoimmune diseases by targeting pathogenic age-associated B cells with liposomal delivery of nucleic acids encoding human DEF6 and SWAP-70 proteins, enhancing efficacy and reducing toxicity.

The original patent disclosed a method of treating autoimmune diseases by administering nucleic acids encoding human DEF6 and SWAP-70 proteins. However, the patent did not address the limitations of systemic administration, which can lead to off-target effects and toxicity. The new inventive concept addresses this limitation by utilizing liposomal delivery to target pathogenic age-associated B cells, enhancing efficacy and reducing toxicity.

The new inventive concept comprises a method of treating autoimmune diseases by administering a therapeutically effective amount of nucleic acids encoding human DEF6 and SWAP-70 proteins, formulated with a liposomal delivery system to target pathogenic age-associated B cells. The liposomal delivery system enhances the efficacy of the treatment by increasing the concentration of the nucleic acids at the site of action, while reducing off-target effects and toxicity. The new inventive concept also includes a system for diagnosing autoimmune diseases, a method of preventing autoimmune diseases, a kit for treating autoimmune diseases, and a method of monitoring autoimmune disease progression.

The new inventive concept is novel and non-obvious in that it combines the administration of nucleic acids encoding human DEF6 and SWAP-70 proteins with liposomal delivery to target pathogenic age-associated B cells, thereby enhancing efficacy and reducing toxicity. This combination is not suggested by the original patent and represents a significant improvement over the prior art.

Alternative embodiments of the new inventive concept may include the use of different types of delivery systems, such as nanoparticles or viral vectors, to target pathogenic age-associated B cells. Additionally, the new inventive concept may be adapted for use in combination with other therapies, such as immunomodulatory agents or biologics, to enhance its efficacy.

The new inventive concept has significant commercial potential in the treatment of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. The market for autoimmune disease treatments is large and growing, with an estimated value of over $100 billion by 2025. The new inventive concept's ability to enhance efficacy and reduce toxicity makes it an attractive option for patients and physicians, and its potential for use in combination with other therapies expands its market potential.